Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether.

@article{Kim1998InclusionCO,
  title={Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether.},
  author={Yangmee Kim and Darlene A Oksanen and Walter Massefski and James F. Blake and Erin M Duffy and Boris A. Chrunyk},
  journal={Journal of pharmaceutical sciences},
  year={1998},
  volume={87 12},
  pages={1560-7}
}
Ziprasidone is an antipsychotic agent indicated primarily for the treatment of schizophrenia. An intramuscular dosage form of ziprasidone was developed using beta-cyclodextrin sulfobutyl ether (SBECD) to solubilize the drug by complexation. Inclusion complexation of ziprasidone mesylate (ZM) with SBECD was studied by circular dichroism (CD) spectroscopy, proton nuclear magnetic resonance (1H NMR) spectroscopy, Monte Carlo simulations, phase-solubility studies, and counterion titration. The… CONTINUE READING